Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | CA9 | Q16790 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.37 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21631387 | 0.85 | RXFP1 (0.53) | RXFP1CA1CA2CA9KDM4E | |
| SCHEMBL2429572 | 0.85 | RXFP1 (0.53) | RXFP1CA1CA2CA9KDM4E | |
| SCHEMBL31387660 | 0.85 | RXFP1 (0.53) | RXFP1CA1CA2CA9KDM4E | |
| SCHEMBL1643973 | 0.84 | RXFP1 (0.56) | RXFP1CA1CA2CA9KDM4E | |
| SCHEMBL31387679 | 0.84 | RXFP1 (0.56) | RXFP1CA1CA2CA9KDM4E | |
| SCHEMBL11015754 | 0.79 | ALDH1A1 (0.46) | RXFP1CA1CA2CA9KDM4E | |
| SCHEMBL7754189 | 0.78 | POLB (0.53) | RXFP1CA1CA2CA9KDM4E | |
| SCHEMBL26921670 | 0.77 | RXFP1 (0.49) | RXFP1CA1CA2CA9KDM4E | |
| SCHEMBL13715404 | 0.77 | KDM4E (0.50) | RXFP1CA1CA2CA9KDM4E | |
| SCHEMBL17072005 | 0.77 | KDM4E (0.50) | RXFP1CA1CA2CA9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170145038-A1 | SUBSTITUTED ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2017-05-25 | — | — | US | disclosed |
| US-9546157-B2 | Asymmetric piperidinyl-substituted ureas as medicines | HELSINN HEALTHCARE SA (CH) | 2017-01-17 | — | — | US | disclosed |
| WO-2015134839-A1 | P-SUBSTITUTED ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2015-09-11 | — | — | WO | disclosed |
| US-20150252021-A1 | p-Substituted Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2015-09-10 | — | — | US | disclosed |
| EP-1003738-B1 | BICYCLIC COMPOUNDS AS LIGANDS FOR 5-HT1 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2003-11-19 | — | — | EP | disclosed |
| US-6391891-B1 | ANTISEROTONINE AGENT; ANXIOLYTIC AGENTS, ANTIDEPRESSANTS | SMITHKLINE BEECHAM PLC (GB) | 2002-05-21 | — | — | US | disclosed |
| CN-1260781-A | Indole derivatives having combined 5HT1A, 5HT1B and 5HT1D receptor antagonist activity | SMITHKLINE BEECHAM PLC (GB) | 2000-07-19 | — | — | CN | disclosed |
| EP-1003738-A1 | BICYCLIC COMPOUNDS AS LIGANDS FOR 5-HT1 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2000-05-31 | — | — | EP | disclosed |
| EP-0975593-A1 | INDOLE DERIVATIVES HAVING COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2000-02-02 | — | — | EP | disclosed |
| WO-1999007700-A1 | BICYCLIC COMPOUNDS AS LIGANDS FOR 5-HT1 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 1999-02-18 | — | — | WO | disclosed |
| WO-1998050358-A1 | INDOLE DERIVATIVES HAVING COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252021-A1 | p-Substituted Asymmetric Ureas and Medical Uses Thereof | UTS2R, GIPR, GPR119 | RXFP1 207/4885CA1 3507/4885CA2 3124/4885 |
| US-20170145038-A1 | SUBSTITUTED ASYMMETRIC UREAS AND MEDICAL USES THEREOF | UTS2R, GHSR, GPR119 | RXFP1 192/4885CA1 2425/4885CA2 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.